



HAL
open science

Assessment of in vivo bone microarchitecture changes in an anti-TNF α treated psoriatic arthritic patient

Enrico Soldati, Lucas Escoffier, Sophie Gabriel, Augustin C. Ogier, Christophe Chagnaud, Jean Mattei, Serge Cammilleri, David Bendahan, Sandrine Guis

► To cite this version:

Enrico Soldati, Lucas Escoffier, Sophie Gabriel, Augustin C. Ogier, Christophe Chagnaud, et al.. Assessment of in vivo bone microarchitecture changes in an anti-TNF α treated psoriatic arthritic patient. PLoS ONE, 2021, 16 (5), pp.e0251788. 10.1371/journal.pone.0251788 . hal-03233052

HAL Id: hal-03233052

<https://hal.science/hal-03233052v1>

Submitted on 3 Jun 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

RESEARCH ARTICLE

Assessment of *in vivo* bone microarchitecture changes in an anti-TNF α treated psoriatic arthritic patient

Enrico Soldati^{1,2,3*}, Lucas Escoffier⁴, Sophie Gabriel⁵, Augustin C. Ogier^{1,6}, Christophe Chagnaud⁴, Jean P. Mattei^{1,4}, Serge Cammilleri⁵, David Bendahan¹, Sandrine Guis^{1,4}

1 Aix-Marseille Université, CNRS, CRMBM-CEMEREM, Marseille, France, **2** Aix-Marseille Université, CNRS, IUSTI, Marseille, France, **3** Aix-Marseille Université, CNRS, ISM, Marseille, France, **4** Aix-Marseille Université, Service de Rhumatologie, AP-HM, Marseille, France, **5** Aix-Marseille Université, Service de Médecine Nucléaire, AP-HM, Institut Fresnel, Marseille, France, **6** Aix-Marseille Université, Université de Toulon, CNRS, LIS, Marseille, France

* enrico.soldati@univ-amu.fr



OPEN ACCESS

Citation: Soldati E, Escoffier L, Gabriel S, Ogier AC, Chagnaud C, Mattei JP, et al. (2021) Assessment of *in vivo* bone microarchitecture changes in an anti-TNF α treated psoriatic arthritic patient. PLoS ONE 16(5): e0251788. <https://doi.org/10.1371/journal.pone.0251788>

Editor: Ewa Tomaszewska, University of Life Sciences in Lublin, POLAND

Received: March 12, 2021

Accepted: May 4, 2021

Published: May 19, 2021

Peer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: <https://doi.org/10.1371/journal.pone.0251788>

Copyright: © 2021 Soldati et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: According to the restrictions imposed by Aix Marseille University and by the local ethics committee regarding patients data sharing, data could be made available

Abstract

Objective

Psoriatic arthritis (PsA) is an inflammatory rheumatic disease, mediated in part by TNF α and associated with bone loss. Anti-TNF α treatment should inhibit this phenomenon and reduce the systemic bone loss. Ultra-high field MRI (UHF MRI) may be used to quantify bone microarchitecture (BM) *in-vivo*. In this study, we quantified BM using UHF MRI in a PsA patient and followed up the changes related to anti-TNF α treatment.

Subjects and methods

A non-treated PsA patient with knee arthritis and 7 gender-matched controls were scanned using a gradient re-echo sequence at UHF MRI. After a year of Adalimumab treatment, the patient underwent a second UHF MRI. A PET-FNa imaging was performed before and after treatment to identify and localize the abnormal metabolic areas. BM was characterized using typical morphological parameters quantified in 32 regions of interest (ROIs) located in the patella, proximal tibia, and distal femur.

Results

Before treatment, the BM parameters were statistically different from controls in 24/32 ROIs with differences reaching up to 38%. After treatment, BM parameters were normalized for 15 out of 24 ROIs. The hypermetabolic areas disclosed by PET-FNa before the treatment partly resumed after the treatment.

Conclusion

Thanks to UHF MRI, we quantified *in vivo* BM anomalies in a PsA patient and we illustrated a major reversion after one year of treatment. Moreover, BM results highlighted that the

upon reasonable request addressed to Monique Bernard (monique.bernard@univ-amu.fr) pending the signature of a MTA approved by Aix Marseille University.

Funding: ES has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No713750. Also, it has been carried out with the financial support of the Regional Council of Provence-Alpes-Côte d'Azur and with the financial support of the A* MIDEX (n° ANR-11-IDEX-0001-02), funded by the "Investissements d'Avenir" project funded by the French Government, managed by the French National Research Agency (ANR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

abnormalities were not only localized in hypermetabolic regions identified by PET-FNa, suggesting that the bone loss was global and not related to inflammation.

Introduction

Psoriatic arthritis (PsA) is an inflammatory rheumatic joint disease associated with psoriasis in which axial and peripheral joints can display an elevated inflammatory status [1]. PsA has been initially described by Moll and Wright as a seronegative inflammatory arthritis that occurs most of the time in the presence of psoriasis [2]. It was initially thought to be rare but recent studies indicated that it might occur in up to 30% of patients with psoriasis [3, 4]. The most commonly involved sites include Achilles tendon, quadriceps tendon, knee, wrist and ankle [5]. These sites are usually assessed using ultrasound imaging which could detect both clinically active and non-active sites. Most of the times sites are clinically active. The main clinical presentations are swollen, tender joints, stiffness and pain, scaly skin patches, nail pitting, eye redness [6] but also asymmetric oligo-arthritis, polyarthritis, dactylitis and enthesitis [1, 7]. The PsA clinical presentation is frequently associated with structural changes such as bone erosion and formation i.e. ankylosis or periostitis [5, 8]. Bone erosion could lead to fragility fractures which is a relevant clinical event and one of the major complication of many bone disorders such as osteoporosis. While the prevalence of osteoporosis in PsA is still a matter of debate [9, 10], previous studies have shown that fragility fractures should be considered when evaluating the global picture of PsA patients [10]. Psoriasis and psoriatic arthritis are characterized by tissue infiltration by activated T cells thereby resulting in an increased TNF α , IL 17 and IL 23 production [7, 11, 12]. Synovial tissue and entheses are more particularly affected [13]. This pro-inflammatory status can be an effective trigger of osteoclasts differentiation and activation through the expression of the receptor activator of nuclear factor kappa B ligand (RANKL) [14].

The increased cell activity and the corresponding elevated inflammatory status due to PsA could be assessed using positron emission tomography (PET), which is able to assess the abnormal accumulation of radiotracer in specific areas [15, 16]. The systemic bone loss resulting in a reduced bone mineral density (BMD) and the role of TNF α antibodies in this process are a matter of debate in psoriatic arthritis [8, 17–21]. Using dual energy X-ray absorptiometry (DXA) [22], reduced BMD (g/cm²) values have been reported in PsA patients as compared to controls and so regardless of sex, menopausal status, or age (lumbar spine 1.112 vs. 1.326; femoral neck 0.870 vs. 1.006; total body 1.125 vs. 1.203) [23]. However, bone micro architecture has never been documented as part of this bone alteration process. Interestingly, magnetic resonance imaging (MRI) and more particularly ultra-high field MRI (UHF MRI) has been reported as a promising tool for the assessment of bone microarchitecture given the high resolution of the corresponding images [24]. Over the last few years, this non-radiating imaging technique has shown promising results regarding spine, knee, and femur trabeculation in osteoporosis [25–27]. So far, the corresponding changes in psoriatic arthritis have never been assessed.

The purpose of the present study was to investigate bone trabeculation in a patient with psoriatic arthritis using UHF MRI and to assess changes related to a TNF α antibodies therapeutic strategy.

Material and methods

Subject recruitment

This study received institutional review board approval by the "Comite de protection des personnes sud Méditerranée I" (approval number 2016-A000427-44). Written informed consent

was obtained from all the recruited subjects. One PsA patient (male, 18 years old, body mass index (BMI) = 14.53 kg/m²) affected by axial and peripheral psoriatic arthritis, was assessed before and after a one-year Adalimumab treatment. The patient experienced knee arthritis six months before the first appointment and had cutaneous *vulgaris psoriasis* in elbow and knee only (Psoriasis Area Severity Index (PASI) = 1.8). The whole set of other pathologies leading to comorbidities and reduced BMI values were excluded. The patient was naïve of any conventional synthetic Disease Modifying Anti-Rheumatic Drug (CsDMARD), biological Disease Modifying Anti-Rheumatic Drug (bDMARD) or targeted synthetic Disease Modifying Anti-Rheumatic Drug (tsDMARD). Seven healthy volunteers with no sign of trabecular bone diseases or osteopenia (all males, mean age = 21.6 years [interquartile range (IQR) = 1 year], mean BMI = 21.32 kg/m² [IQR = 1.29 kg/m²]) were included in the control group.

MRI scanning

The patient and the volunteers underwent 7T MRI (MAGNETOM, Siemens Healthineers, Germany) of the knee joint (distal femur, proximal tibia and patella). All subjects were scanned using a 28-channel knee coil and a 3D gradient recalled echo sequence (3D GRE, TR/TE = 15/4.36 ms, flip angle = 12°, bandwidth = 326 Hz/pixel, field of view = 180*180 mm, matrix = 768 x 768, in-plane voxel dimension 0.234 x 0.234 mm, slice thickness = 1.5 mm, 64 sagittal planes, acquisition time = 5 minutes 56 seconds). This protocol is similar to what has been previously used for knee scanning at 3T [28, 29]. The PsA patient was scanned once before treatment and once after one year of treatment. During MRI scanning, the patients' knee was immobilized by sandbags and secured by Velcro straps to avoid involuntary movements.

PET scanning

As part of the usual follow-up procedure, the PsA patient underwent two CT/PET FNa scanning, once before treatment and once after one year of treatment. The sodium fluoride radiotracer (Cisnaf©) was administrated intravenously (3MBq/kg) and images were acquired 60 min after the injection on a Biograph 16 tomograph (Siemens, Healthineers, Germany), coupled to a low dose CT scanner with standard parameters (CT: 80 mA, 120 kV without contrast; 2 min per bed-PET- step of 15 cm) [30, 31]. CT/PET FNa images were iteratively reconstructed in a 128x128 matrix and 60 cm field of view, with and without attenuation correction in the transaxial, coronal and sagittal planes. The patient did not require special preparation. He was asked to be hydrated in order to activate the rapid washout of the radiotracer, to reduce the radiation dose and to improve the images quality.

PET-MRI fusion

MR and CT/PET FNa images [30] were acquired using two different scanners. Given that bones were clearly visible in both CT and MR images, the four bones (femur, tibia, fibula, and patella) were used as landmarks for the registration of both images. More specifically, bones were delineated semi-automatically in each stack of images and linear affine registrations were computed independently between each bone using FSL-FLIRT [32]. Each local affine transformation was then merged into a global 3D deformation field through the implementation (described in [33]) of the log-euclidean poly-affine framework proposed by Arsigny et al. [34]. The resulting deformation field was used to overlay the PET maps on the highly resolved and contrasted 7T MR anatomical images as previously reported [35] (Fig 1).




Fig 1. Merged PET-UHF MRI. Sagittal, coronal, and axial plane of merged PET-UHF MRI of the knee articulation of the patient before (A) and after (B) treatment by TNF-antibodies. “[Ad]” refers to a dimensional. Values higher or equal to 2.5 are considered indicative of “hypermetabolic” activity.

<https://doi.org/10.1371/journal.pone.0251788.g001>

PET-MR analysis

Fused PET-MR images were visually evaluated by an expert (SG) with the aim of identifying and localizing the hypermetabolic regions before and after the treatment. The visual inspection of fused images was crucial in order to identify the regions with hyperintense signals.

Bone volume fraction maps representing the relative volume of bone within each voxel were generated from the GRE images. The initial images were linearly scaled in order to cover the range from 0 (pure bone) to 255 (pure marrow) [36, 37]. In each image, distal femur, proximal tibia and patella were delineated using the Chan-Vese algorithm, which showed to be robust for the separation between bone, tendons and cartilage in the knee [38, 39]. The corresponding filled contours were used as masks on which a 10-pixels closing process was applied (2.34 mm) in all directions in order to eliminate all the cortical bone (Fig 2). Several region of interests (ROI) were identified in different locations of the trabecular bone in order to fully investigate the trabecular network.




Fig 2. ROIs identification. PsA patient after treatment BVF maps showing the multiple ROIs identified in red.

<https://doi.org/10.1371/journal.pone.0251788.g002>

ROIs selection. The ROIs selection was based on the PET-FNa results. Accordingly they were selected in regions with hyper-intense signals before the Adalimumab treatment and were selected in the same regions after the treatment regardless of the signal intensity.

Patella. The first set of ROIs (ROI1, ROI1a, ROI1b and ROI1c) were located in the patella region and referred respectively to the trabecular space of the whole patella, the upper and lower third of the trabecular region where the quadriceps and patellar tendons are respectively attached and the central third of the patella (Fig 2).

Distal Femur. ROI2 was located in the distal femur epiphysis as illustrated in Fig 2.

Proximal Tibia. The final set of ROIs (ROI3, ROI3a and ROI3b) were positioned in the proximal tibia. ROI3 refers to the trabecular space of the proximal tibia epiphysis. ROI3a represents the trabecular part of the tibia where the medial collateral ligament is attached and ROI3b represents the trabecular part of the tibia where there was no hypermetabolic activity on the basis of the PET FNa signal. (Fig 2).

Bone microstructure evaluation. To reduce the computational costs from the 3D ROIs, three 2D centrally located MRI planes were selected for each subject i.e. the image with the highest ROI surface together with the N_{+1} and N_{-1} images.

ROIs were then binarized using an automatic local thresholding as previously described [40] and three independent metrics were computed. The bone volume fraction (BVF) which refers to the ratio between bone and the total volume, the trabecular thickness (Tb.Th) and spacing (Tb.Sp). Tb.Th and Tb.Sp were extrapolated using iMorph [41] which can generate an aperture map (AM) derived from a distance transformation map. The AM was retrieved from the maximal balls diameter enclosed in the bone (Tb.Th) and in the marrow (Tb.Sp) phases (Fig 2). Finally the trabecular number (Tb.N) was computed as the ratio between the BVF and the Tb.Th.

Student's T-tests were used in order to assess the morphological parameters differences between the control group and the PsA patient before and after the TNF treatment. For each subject, three measurements were obtained for each metric and each ROI. A p-value lower than 0.01 was considered as significant.

Standardized uptake values. A semi-quantitative analysis of PET images was performed as previously described in order to generate the Standardized Uptake Values (SUV) [15, 30]. SUV were computed as the ratio between the signal intensity within each pixel of the image scaled to the concentration of the total injected radioactivity (3 MBq/Kg). The corresponding

results refer the pixel-based metabolic. A SUV of 2.5 or higher is generally considered to be indicative of an “hypermetabolic” region. Finally, mean and maximal values were computed within each ROI.

Results

PET-FNa

Hypermetabolism evolution. The visual inspection of the initial set of PET images showed intense polyarticular hyperintense signals preferentially involving the knees, the left hip, the right ankle, the elbows, and more moderately the spine, the feet and the hands. As illustrated in Fig 1, large hyperintensities were observed in the knee. The second set of PET image recorded after one year of treatment, showed an unequivocal reduction in most of the hypermetabolic regions affecting the joints of the axial and appendicular skeleton and more particularly the knee. The whole set of ROIs showed reduced hyperintensities whereas no more hyperintense signal was visible for ROI2 and ROI3b.

SUV results. SUV were quantified in all the knees ROIs before and after one year of treatment and the corresponding values are indicated in Table 1. Before the treatment, SUVmean was abnormal in 5 over 8 ROIs. The abnormal values were concentrated in all the patellar ROIs (2.7 ± 0.1) and ROI3a (2.8). SUVmax averaged over the whole set of ROIs was 3.67 ± 0.41 . After the treatment, SUV were no longer larger than 2.5 in almost all the ROIs while the averaged SUVmax was also significantly reduced i.e. 2.86 ± 0.86 . Large SUV values (i.e. between 1.7 and 2.5) were still visible in all the patella ROIs and ROI3a (Table 1).

MRI microarchitecture

Regarding the MRI-based micro-architecture measurements performed before the treatment, the patient was outside the control range for multiple metrics and multiple localizations (24 out of 32 measurements were statistically different from the controls). However, after one year of treatment the microarchitectural parameters differences between the PsA patient and the healthy references were reduced and the parameters were approaching or within the control range (only 9 out of 32 measurements were still statistically different than controls) (Table 2).

Patella. Before the treatment and considering the four ROIs delineated in the patellar region, BVF of the patient was always significantly lower as compared to controls with a mean difference of $-23 \pm 10\%$. The Tb.Th difference was always below 5% ($p > 0.01$ for all the four ROIs), with a general mean of 0.25 ± 0.03 mm for the controls and 0.24 ± 0.02 mm for the

Table 1. SUV results before and after treatment for all identified ROIs.

	Before Treatment		After Treatment	
	SUVmean	SUVmax	SUVmean	SUVmax
ROI1	2.7 ± 0.5	3.79	2.1 ± 0.6	3.77
ROI1a	2.6 ± 0.4	3.72	2.4 ± 0.4	3.18
ROI1b	2.9 ± 0.5	3.77	1.6 ± 0.5	3.02
ROI1c	2.7 ± 0.4	3.79	2.3 ± 0.6	3.69
ROI2	1.9 ± 0.5	3.34	1.2 ± 0.6	3.32
ROI3	1.9 ± 0.5	4.06	1.0 ± 0.3	2.41
ROI3a	2.8 ± 0.4	4.06	1.3 ± 0.4	2.41
ROI3b	2.0 ± 0.2	2.82	0.7 ± 0.1	1.12

SUV mean (SUVmean) values are presented as mean \pm SD and SUV maximum (SUVmax) values of the investigated ROIs before and after one year of treatment.

<https://doi.org/10.1371/journal.pone.0251788.t001>

Table 2. Microarchitecture characteristics per ROI.

			Controls	P. before treatment	P. after Treatment
Patella	ROI1	BVF	0.375±0.015	0.297±0.011 *	0.373±0.016
		Tb.Th	0.258±0.005	0.257±0.004	0.276±0.003 *
		Tb.Sp	0.429±0.065	0.643±0.036 *	0.470±0.013
		Tb.N	1.455±0.076	1.132±0.068 *	1.347±0.008
	ROI1a	BVF	0.393±0.008	0.339±0.018 *	0.401±0.010
		Tb.Th	0.255±0.013	0.254±0.022	0.266±0.014
		Tb.Sp	0.364±0.032	0.477±0.058	0.365±0.008
		Tb.N	1.550±0.074	1.301±0.136	1.493±0.073
	ROI1b	BVF	0.355±0.035	0.222±0.064 *	0.328±0.027
		Tb.Th	0.261±0.010	0.250±0.015	0.285±0.004 *
		Tb.Sp	0.469±0.117	0.651±0.057 *	0.532±0.064
		Tb.N	1.366±0.114	0.994±0.090 *	1.116±0.083
	ROI1c	BVF	0.377±0.015	0.295±0.026 *	0.375±0.016
		Tb.Th	0.207±0.008	0.213±0.005	0.225±0.003 *
		Tb.Sp	0.366±0.042	0.632±0.096 *	0.424±0.005
		Tb.N	1.746±0.250	1.409±0.119 *	1.661±0.024
Distal Femur	ROI2	BVF	0.354±0.048	0.257±0.015 *	0.312±0.007
		Tb.Th	0.261±0.005	0.260±0.006	0.269±0.006
		Tb.Sp	0.516±0.140	0.769±0.025 *	0.656±0.009
		Tb.N	1.342±0.187	1.016±0.020 *	1.173±0.054
Proximal Tibia	ROI3	BVF	0.337±0.019	0.219±0.015 *	0.256±0.012 *
		Tb.Th	0.266±0.011	0.245±0.004 *	0.257±0.008
		Tb.Sp	0.562±0.087	0.924±0.029 *	0.866±0.053 *
		Tb.N	1.261±0.109	0.879±0.051 *	0.985±0.043 *
	ROI3a	BVF	0.381±0.009	0.307±0.016 *	0.335±0.018
		Tb.Th	0.258±0.008	0.260±0.009	0.267±0.012
		Tb.Sp	0.426±0.060	0.594±0.012 *	0.570±0.016 *
		Tb.N	1.468±0.073	1.185±0.047 *	1.241±0.029 *
	ROI3b	BVF	0.376±0.018	0.242±0.024 *	0.285±0.013 *
		Tb.Th	0.220±0.015	0.192±0.005 *	0.202±0.011
		Tb.Sp	0.418±0.061	0.636±0.054 *	0.539±0.033
		Tb.N	1.689±0.148	1.255±0.183 *	1.432±0.094

Data are presented as mean ± SD. "P." refers as patient. BVF: Bone volume fraction, Tb.Th: Trabecular Thickness, Tb.Sp: Trabecular Space, Tb.N: Trabecular number. * indicates a statistically significant difference ($p < 0.01$) with the Healthy reference values.

<https://doi.org/10.1371/journal.pone.0251788.t002>

patient. The Tb.Sp difference was statistically significant for ROI1, ROI1b and ROI1c but not for ROI1a with the patient having larger trabecular spaces as compared to controls and therefore a positive difference mean of $48 \pm 18\%$. Similar results were found for Tb.N and a significant difference was found for ROI1, ROI1b and ROI1c but not for ROI1a with a general mean difference of $-21 \pm 5\%$.

Following the 12-month TNF treatment, most of the micro-architecture metrics but Tb.Th reversed to normal values. BVF increased in the four patella's ROIs thereby reducing the differences with controls to a non-significant mean value of $-2 \pm 4\%$. Similar results were quantified for Tb.Sp and Tb.N with a non-significant difference with controls for any of the patella's ROIs and a new overall patient mean difference of $10 \pm 7\%$ for Tb.Sp and $-9 \pm 7\%$ for Tb.N. On




Fig 3. ROI1a extrapolated features box plot. Box plot for each extrapolated feature for the control reference (Healthy), patient before (P_before) and after (P_after) one year of anti-TNF α treatment in the trabecular region where the quadricep tendon attaches the patella (ROI1a).

<https://doi.org/10.1371/journal.pone.0251788.g003>

the contrary, after the treatment, Tb.Th became significantly larger with a significant difference (up to 9%) with controls and so for ROI1, ROI1b and ROI1c (Fig 3 and Table 2).

Distal femur. In the distal femur (ROI2) the difference between the healthy reference and the patient before the treatment was more than 20% for all the parameters (-27% for BVF, 49% for Tb.Sp and -24% for Tb.N) except for Tb.Th for which the difference was less than 1%.

The image analysis after the treatment still showed increased BVF and Tb.N values while Tb.Sp values were reduced. The corresponding differences between the patient and the control values were -12%, -13% and +27% respectively. Similar to the results found in the patella, the Tb.Th increased becoming 3% thicker than controls. The difference between the control and the patient values after the treatment was statistically significant ($p > 0.01$) for none of the micro-architectural parameters evaluated (Table 2).

Proximal tibia. The three ROIs (ROI3, ROI3a and ROI3b) located in the proximal tibia region also showed statistically differences between patient and control values for the whole set of MRI metrics. The only normal value was found for Tb.Th in ROI3a. More particularly, the differences between the patient and the controls were $-30 \pm 9\%$ for BVF, $52 \pm 12\%$ for Tb.Sp, $-25 \pm 6\%$ for Tb.N and $-7 \pm 7\%$ for Tb.Th.

After the 12 month-TNF treatment, the bone microstructure differences were reduced, although remaining statistically significant in most of the cases. For the BVF, the difference was reduced to $-20 \pm 7\%$ and remained statistically significant for ROI3 and ROI3b. The Tb.Th difference was also reduced to $-3 \pm 6\%$ thereby becoming not statistically significant for any of the three tibial ROIs. The Tb.Sp difference slightly decreased to $39 \pm 13\%$ but remained statistically significant ($p < 0.01$) for ROI3 and ROI3a but not for ROI3b. The Tb.N difference also decreased to $-18 \pm 4\%$ but remained statistically significant for ROI3 and ROI3a but not for ROI3b (Table 2).

Discussion

In the present study, we assessed bone microarchitecture in a PsA patient in order to document the potential bone quality changes associated with his inflammatory status. We also assessed the microarchitecture modification resulting from a one-year anti-TNF treatment. We mainly found that PET-FNa/MRI showed a largely inflamed knee articulation with some specific hypermetabolic regions in the vicinity of ligament and tendons in the patella, the distal femur, and the proximal tibia. Microarchitectural changes quantified using UHF MRI were affecting the whole bone segments and were not localized within the hypermetabolic regions only. After a year of TNF treatment, the combined PET-UHF MRI approach showed highly reduced hypermetabolic regions and an improvement for most of the microarchitectural parameters and the BMI increased from 14.5 to 18.9 kg/m^2 reaching the normal range (18.5 – 24.9 kg/m^2) [42].

Before the treatment, all the microarchitecture metrics were significantly different with respect to the control values and so in at least one ROI. Using HR-pQCT on the distal radius of a group of 50 PsA patients and comparing the bone microarchitecture results to those from controls, Kocijan *et al.* reported significantly reduced BVF and Tb.N, increased Tb.Sp and almost constant Tb.Th [12]. Compared to our study, Kocijan *et al.* reported lower bone microstructure parameters differences between PsA patients and controls (-11.9%, -7.1%, +9.1%, -1.5% respectively for BVF, Tb.N, Tb.Sp and Tb.Th vs. an overall difference mean for all the ROIs analysed of -26% for BVF, -23% for Tb.N, +50% for Tb.Sp and -3% for Tb.Th). However, these discrepancies could be explained by the different anatomical investigated sites (distal radii vs. knee articulation) and by the age and body mass index of the PsA patients (51±13y, 27.9±5.1 kg/m² vs. 18y, 14.5 kg/m²). Although previous DXA measurements have been controversial regarding BMD changes in PsA patients [8, 17, 18], our results further support those obtained using a radiating imaging technique and confirm abnormalities of trabecular bone in PsA patients so that osteoporotic changes might be expected in PsA.

In the field of rheumatologic inflammatory disorders, our study is the first to address the bone microarchitecture issue using UHF MRI, although previous studies involving the use of UHF MRI have reported promising results in osteoporosis [25–27, 43]. As an example, Chang *et al.* [25] found abnormal trabecular characteristics including BVF in the distal femur of subjects with fragility fractures whereas the DXA T-score was normal. Of interest, BVF, Tb.Sp and Tb.N were abnormal in the majority (7/8) of ROIs in the present study whereas Tb.Th was abnormal in a limited number (2/8) of ROIs. These results further support those previously reported by Kocijan *et al.* [12] and Chang *et al.* [25] regarding the larger sensitivity of BVF, Tb.Sp and Tb.N to bone micro-architecture alterations as compared to Tb.Th. In fact, Kocijan *et al.* [12] reported no difference in Tb.Th between PA patients and healthy controls in distal radii while Chang *et al.* [25] found normal distal femur Tb.Th in patients with fragility fractures.

Trabecular abnormalities detected using UHF MRI were found in all the hypermetabolic regions detected using PET-FNa, showing that microarchitecture deterioration was affecting the whole bone segments. The PET analysis has been shown to reflect bone remodelling and has been used in several studies on osteoporosis [44–47]. In our case, PET-FNa allowed to localize specific ROIs characterized by elevated hypermetabolic activity before treatment and ROIs presenting partial or full remission after treatment.

After a year of anti-TNF treatment, the trabecular parameters clearly illustrated that the knee of the patient was in clinical remission from his PsA status. The trabecular parameters reversal might result from the decreased inflammatory status leading to a reduced osteoclastic bone resorption activity. In PsA, Hoff *et al.* [20] have showed that 24 weeks of Infliximab treatment can stop the bone loss. In multiple studies conducted in rheumatoid arthritis (RA) patients, the TNF blocking strategy has been associated with an increase of biological markers indicating bone formation and a decrease of those illustrating bone resorption [48–50]. In both RA and Ankylosing spondylitis (AS), the efficiency of anti-TNF agents on bone loss has also been confirmed through BMD measurements using DXA [49–53]. Our PET-FNa/MRI measurements also supported the efficiency of the anti-TNF strategy. In fact, UHF MRI allowed us to assess and quantify the microarchitectural parameters in the hypermetabolic ROIs assessed through the PET-FNa. In our study, UHF MRI showed an almost homogeneous microarchitecture deterioration before treatment and a partial or a complete remission after one year of treatment. These results are also in agreement with those previously reported as a result of bisphosphonates treatment in osteoporotic patients [45, 47].

A few limitations have to be acknowledged in the present study. Although, this preliminary study was conducted in a PsA patient, we have quantified morphological parameters in several

UHF MR images from 3 different bone segments (patella, distal femur, and proximal tibia) and using 8 different ROIs. Moreover, the results of the PsA patient were compared both temporally, i.e. before and after the treatment, and against the control group. One might wonder whether the reported changes are gender specific given that we assessed male subjects only and the inclusion of female subjects would be of interest. Additionally, it could be of interest to assess other bones regions with an elevated bone turnover such as the sacroiliac joint, spine and other peripheral joints. However, one has to keep in mind that the availability of dedicated coils for UHF MRI is rather reduced. One could also argue that partial volume effects might have biased the results. Such an effect can occur when pixels size in a given MR image is larger than the trabecular thickness (100 μm). Our protocol was similar to previously reported knee MRI acquisitions [28, 29]. The partial volume error if any was expected to be the same for all the MR images so that the comparison was still valid.

The investigation of bone microarchitecture in patients affected by PsA is of interest for a reliable assessment of bone quality, illness risk stratification and for the follow-up of therapeutic strategy. Up to now, PsA patients have been mainly treated using CsDMARD, bDMARD and tsDMARD [54] and the effects on bone microarchitecture have never been documented. However, the administration of anti-TNF may inhibit the osteoclastic action of bone resorption triggered by the inflammatory response. Moreover, the application of UHF MRI might be of high interest to investigate bone microarchitecture in the future for specific clinical situations.

Author Contributions

Conceptualization: David Bendahan, Sandrine Guis.

Data curation: Enrico Soldati, Lucas Escoffier, Augustin C. Ogier.

Formal analysis: Enrico Soldati.

Funding acquisition: David Bendahan, Sandrine Guis.

Investigation: Enrico Soldati, Lucas Escoffier, Sophie Gabriel, Jean P. Mattei, Serge Cammilleri, David Bendahan, Sandrine Guis.

Methodology: Enrico Soldati, Sophie Gabriel, Jean P. Mattei, Serge Cammilleri, David Bendahan, Sandrine Guis.

Project administration: David Bendahan, Sandrine Guis.

Resources: Sophie Gabriel, Christophe Chagnaud, Jean P. Mattei, Serge Cammilleri, David Bendahan, Sandrine Guis.

Software: Enrico Soldati.

Supervision: David Bendahan, Sandrine Guis.

Validation: Enrico Soldati, Lucas Escoffier, David Bendahan, Sandrine Guis.

Visualization: Enrico Soldati, David Bendahan, Sandrine Guis.

Writing – original draft: Enrico Soldati, Lucas Escoffier.

Writing – review & editing: David Bendahan, Sandrine Guis.

References

1. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. *Lancet*. 2007; 370: 263–271. [https://doi.org/10.1016/S0140-6736\(07\)61128-3](https://doi.org/10.1016/S0140-6736(07)61128-3) PMID: 17658397

2. Moll JM, Wright V. Psoriatic arthritis. *Semin Arthritis Rheum*. 1973; 3: 55–78. [https://doi.org/10.1016/0049-0172\(73\)90035-8](https://doi.org/10.1016/0049-0172(73)90035-8) PMID: 4581554
3. Ogdie A, Weiss P. The Epidemiology Psoriatic Arthritis. *Rheum Dis Clin North Am*. 2015; 41: 545–568. <https://doi.org/10.1016/j.rdc.2015.07.001> PMID: 26476218
4. Villani AP, Rouzaud M, Sevrain M, Barnetche T, Paul C, Richard M-A, et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis. *J Am Acad Dermatol*. 2015; 73: 242–248. <https://doi.org/10.1016/j.jaad.2015.05.001> PMID: 26054432
5. Tang Y, Cheng S, Yang Y, Xiang X, Wang L, Zhang L, et al. Ultrasound assessment in psoriatic arthritis (PsA) and psoriasis vulgaris (non-PsA): which sites are most commonly involved and what features are more important in PsA? *Quant Imaging Med Surg*. 2020; 10: 86–95. <https://doi.org/10.21037/qims.2019.08.09> PMID: 31956532
6. Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. *Clin Med*. 2017; 17: 65–70. <https://doi.org/10.7861/clinmedicine.17-1-65> PMID: 28148584
7. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic Arthritis. Longo DL, editor. *N Engl J Med*. 2017; 376: 957–970. <https://doi.org/10.1056/NEJMra1505557> PMID: 28273019
8. Perez-Chada LM, Merola JF. Comorbidities associated with psoriatic arthritis: Review and update. *Clin Immunol*. 2020; 214: 108397. <https://doi.org/10.1016/j.clim.2020.108397> PMID: 32229290
9. Attia EAS, Khafagy A, Abdel-Raheem S, Fathi S, Saad AA. Assessment of osteoporosis in psoriasis with and without arthritis: correlation with disease severity: Assessment of osteoporosis in psoriasis. *International Journal of Dermatology*. 2011; 50: 30–35. <https://doi.org/10.1111/j.1365-4632.2010.04600.x> PMID: 21182499
10. Del Puente A, Esposito A, Costa L, Benigno C, Del Puente A, Foglia F, et al. Fragility Fractures in Patients with Psoriatic Arthritis. *The Journal of Rheumatology Supplement*. 2015; 93: 36–39. <https://doi.org/10.3899/jrheum.150633> PMID: 26523054
11. Leijten EFA, van Kempen TS, Boes M, Michels-van Amelsfort JMR, Hijnen D, Hartgring SAY, et al. Brief report: enrichment of activated group 3 innate lymphoid cells in psoriatic arthritis synovial fluid. *Arthritis & Rheumatology (Hoboken, NJ)*. 2015; 67: 2673–2678. <https://doi.org/10.1002/art.39261> PMID: 26137857
12. Kocijan R, Englbrecht M, Haschka J, Simon D, Kleyer A, Finzel S, et al. Quantitative and Qualitative Changes of Bone in Psoriasis and Psoriatic Arthritis Patients. *J Bone Miner Res*. 2015; 30: 1775–1783. <https://doi.org/10.1002/jbmr.2521> PMID: 25827104
13. Menon B, Gullick NJ, Walter GJ, Rajasekhar M, Garrood T, Evans HG, et al. Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. *Arthritis & Rheumatology (Hoboken, NJ)*. 2014; 66: 1272–1281. <https://doi.org/10.1002/art.38376> PMID: 24470327
14. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. *J Clin Invest*. 2003; 111: 821–831. <https://doi.org/10.1172/JCI16069> PMID: 12639988
15. Rosen D, Herrington B, Bhargava P, Laucirica R, Verstovsek G. Correlation of Tissue Biopsy and Fine Needle Aspiration Cytology with Positron Emission Tomography Results. *Pathology Research International*. 2011; 2011: 1–7. <https://doi.org/10.4061/2011/323051> PMID: 21559200
16. Chaudhari AJ, Ferrero A, Godinez F, Yang K, Shelton DK, Hunter JC, et al. High-resolution ¹⁸F-FDG PET/CT for assessing disease activity in rheumatoid and psoriatic arthritis: findings of a prospective pilot study. *BJR*. 2016; 89: 20160138. <https://doi.org/10.1259/bjr.20160138> PMID: 27109738
17. Ogdie A, Harter L, Shin D, Baker J, Takeshita J, Choi HK, et al. The risk of fracture among patients with psoriatic arthritis and psoriasis: a population-based study. *Ann Rheum Dis*. 2017; 76: 882–885. <https://doi.org/10.1136/annrheumdis-2016-210441> PMID: 28093419
18. Chandran S, Aldei A, Johnson SR, Cheung AM, Salonen D, Gladman DD. Prevalence and risk factors of low bone mineral density in psoriatic arthritis: A systematic review. *Semin Arthritis Rheum*. 2016; 46: 174–182. <https://doi.org/10.1016/j.semarthrit.2016.05.005> PMID: 27346576
19. Di Munno O, Ferro F. The effect of biologic agents on bone homeostasis in chronic inflammatory rheumatic diseases. *Clin Exp Rheumatol*. 2019; 37: 502–507. PMID: 30557124
20. Hoff M, Kavanaugh A, Haugeberg G. Hand bone loss in patients with psoriatic arthritis: posthoc analysis of IMPACT II data comparing infliximab and placebo. *J Rheumatol*. 2013; 40: 1344–1348. <https://doi.org/10.3899/jrheum.121376> PMID: 23772084
21. Maruotti N, Corrado A, Cantatore FP. Osteoporosis and rheumatic diseases. *Reumatismo*. 2014; 66: 125–135. <https://doi.org/10.4081/reumatismo.2014.785> PMID: 25069494

22. Briot K, Roux C, Thomas T, Blain H, Buchon D, Chapurlat R, et al. 2018 update of French recommendations on the management of postmenopausal osteoporosis. *Joint Bone Spine*. 2018; 85: 519–530. <https://doi.org/10.1016/j.jbspin.2018.02.009> PMID: 29654947
23. Frediani B, Allegri A, Falsetti P, Storri L, Bisogno S, Baldi F, et al. Bone Mineral Density in Patients with Psoriatic Arthritis. *The Journal of Rheumatology*.: 6.
24. Chang G, Boone S, Martel D, Rajapakse CS, Hallyburton RS, Valko M, et al. MRI Assessment of Bone Structure and Microarchitecture. *J Magn Reson Imaging*. 2017; 46: 323–337. <https://doi.org/10.1002/jmri.25647> PMID: 28165650
25. Chang G, Honig S, Liu Y, Chen C, Chu KK, Rajapakse CS, et al. 7 Tesla MRI of bone microarchitecture discriminates between women without and with fragility fractures who do not differ by bone mineral density. *J Bone Miner Metab*. 2015; 33: 285–293. <https://doi.org/10.1007/s00774-014-0588-4> PMID: 24752823
26. Guenoun D, Fouré A, Pithioux M, Guis S, Le Corroller T, Mattei J-P, et al. Correlative Analysis of Vertebral Trabecular Bone Microarchitecture and Mechanical Properties: A Combined Ultra-high Field (7 Tesla) MRI and Biomechanical Investigation. *Spine*. 2017; 42: E1165–E1172. <https://doi.org/10.1097/BRS.0000000000002163> PMID: 28338579
27. Guenoun D, Pithioux M, Souplet J-C, Guis S, Le Corroller T, Fouré A, et al. Assessment of proximal femur microarchitecture using ultra-high field MRI at 7 Tesla. *Diagn Interv Imaging*. 2020; 101: 45–53. <https://doi.org/10.1016/j.diii.2019.06.013> PMID: 31331831
28. Chiba K, Uetani M, Kido Y, Ito M, Okazaki N, Taguchi K, et al. Osteoporotic changes of subchondral trabecular bone in osteoarthritis of the knee: a 3-T MRI study. *Osteoporos Int*. 2012; 23: 589–597. <https://doi.org/10.1007/s00198-011-1585-2> PMID: 21359670
29. Bolbos RI, Zuo J, Banerjee S, Link TM, Benjamin Ma C, Li X, et al. Relationship between trabecular bone structure and articular cartilage morphology and relaxation times in early OA of the knee joint using parallel MRI at 3T. *Osteoarthritis and Cartilage*. 2008; 16: 1150–1159. <https://doi.org/10.1016/j.joca.2008.02.018> PMID: 18387828
30. de Arcocha M, Portilla-Quattrociocchi H, Medina-Quiroz P, Carril JM. Estado actual del uso del (18F) fluoruro sódico en la patología ósea. *Revista Española de Medicina Nuclear e Imagen Molecular*. 2012; 31: 51–57. <https://doi.org/10.1016/j.rem.2011.05.008> PMID: 21794957
31. Albano D, Giubbini R, Bertagna F. 18F-FDG PET/CT in splenic marginal zone lymphoma. *Abdom Radiol*. 2018; 43: 2721–2727. <https://doi.org/10.1007/s00261-018-1542-z> PMID: 29500652
32. Jenkinson M, Bannister P, Brady M, Smith S. Improved Optimization for the Robust and Accurate Linear Registration and Motion Correction of Brain Images. *NeuroImage*. 2002; 17: 825–841. [https://doi.org/10.1016/s1053-8119\(02\)91132-8](https://doi.org/10.1016/s1053-8119(02)91132-8) PMID: 12377157
33. Makki K, Borotikar B, Garetier M, Brochard S, Ben Salem D, Rousseau F. In vivo ankle joint kinematics from dynamic magnetic resonance imaging using a registration-based framework. *Journal of Biomechanics*. 2019; 86: 193–203. <https://doi.org/10.1016/j.jbiomech.2019.02.007> PMID: 30824237
34. Arsigny V, Commowick O, Ayache N, Pennec X. A Fast and Log-Euclidean Polyaffine Framework for Locally Linear Registration. *J Math Imaging Vis*. 2009; 33: 222–238. <https://doi.org/10.1007/s10851-008-0135-9>
35. Cammilleri S, Gabriel S, Le Troter A, Chagnaud C, Mattei JP, Bendahan D, et al. Knee psoriatic enthesitis assessed using positron emission tomography (PET)—FNa merged to ultrahigh field magnetic resonance imaging (UHF-MRI). *Joint Bone Spine*. 2019; 86: 387–388. <https://doi.org/10.1016/j.jbspin.2019.01.002> PMID: 30660806
36. Chang G, Rajapakse CS, Regatte RR, Babb J, Saxena A, Belmont HM, et al. 3 Tesla MRI detects deterioration in proximal femur microarchitecture and strength in long-term glucocorticoid users compared with controls: Changes in Proximal Femur Microarchitecture in GIO. *J Magn Reson Imaging*. 2015; 42: 1489–1496. <https://doi.org/10.1002/jmri.24927> PMID: 26073878
37. Rajapakse CS, Leonard MB, Bhagat YA, Sun W, Magland JF, Wehrli FW. Micro-MR Imaging-based Computational Biomechanics Demonstrates Reduction in Cortical and Trabecular Bone Strength after Renal Transplantation. *Radiology*. 2012; 262: 912–920. <https://doi.org/10.1148/radiol.11111044> PMID: 22357891
38. Jiang J-G, Guo Y, Zhan S, Li H. Segmentation of Knee Joints Based on Improved Multiphase Chan-Vese Model. 2008 2nd International Conference on Bioinformatics and Biomedical Engineering. Shanghai, China: IEEE; 2008. pp. 2418–2422. <https://doi.org/10.1109/ICBBE.2008.937>
39. Aprovitola A, Gallo L. Knee bone segmentation from MRI: A classification and literature review. *Biocybernetics and Biomedical Engineering*. 2016; 36: 437–449. <https://doi.org/10.1016/j.bbe.2015.12.007>
40. Dougherty R, Kunzelmann K-H. Computing Local Thickness of 3D Structures with ImageJ. *MAM*. 2007;13. <https://doi.org/10.1017/S1431927607074430>

41. Brun E, Ferrero C, Vicente J. Fast Granulometry Operator for the 3D Identification of Cell Structures. Dulio P, Frosini A, Rozenberg G, editors. *FI*. 2017; 155: 363–372. <https://doi.org/10.3233/FI-2017-1590>
42. Weir C, Jan A. BMI Classification Percentile and Cut Off Points. Treasure Island (FL): StatPearls Publishing; 2020. Available: <https://www.ncbi.nlm.nih.gov/books/NBK541070/>
43. Soldati E, Rossi F, Vicente J, Guenoun D, Pithioux M, Iotti S, et al. Survey of MRI Usefulness for the Clinical Assessment of Bone Microstructure. *IJMS*. 2021; 22: 2509. <https://doi.org/10.3390/ijms22052509> PMID: 33801539
44. Blake GM, Park-Holohan S-J, Fogelman I. Quantitative Studies of Bone in Postmenopausal Women Using 18F-Fluoride and 99mTc-Methylene Diphosphonate. *J Nucl Med*. 2002; 43: 338–345. PMID: 11884493
45. Frost ML, Cook GJR, Blake GM, Marsden PK, Benatar NA, Fogelman I. A prospective study of risedronate on regional bone metabolism and blood flow at the lumbar spine measured by 18F-fluoride positron emission tomography. *J Bone Miner Res*. 2003; 18: 2215–2222. <https://doi.org/10.1359/jbmr.2003.18.12.2215> PMID: 14672357
46. Raynor W, Ayubcha C, Shamchi SP, Zadeh MZ, Emamzadehfard S, Werner T, et al. Assessing global uptake of 18F-sodium fluoride in the femoral neck: a novel quantitative technique to evaluate changes in bone turnover with age. *J Nucl Med*. 2017; 58: 1223–1223.
47. Uchida K, Nakajima H, Miyazaki T, Yayama T, Kawahara H, Kobayashi S, et al. Effects of alendronate on bone metabolism in glucocorticoid-induced osteoporosis measured by 18F-fluoride PET: a prospective study. *J Nucl Med*. 2009; 50: 1808–1814. <https://doi.org/10.2967/jnumed.109.062570> PMID: 19837766
48. Vis M, Wolbink G, Lodder MC, Kostense PJ, Stadt RJ van de, Koning MHMT de, et al. Early changes in bone metabolism in rheumatoid arthritis patients treated with infliximab. *Arthritis & Rheumatism*. 2003; 48: 2996–2997. <https://doi.org/10.1002/art.11292> PMID: 14558111
49. Vis M, Havaardsholm EA, Haugeberg G, Uhlig T, Voskuyl AE, van de Stadt RJ, et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFKappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2006; 65: 1495–1499. <https://doi.org/10.1136/ard.2005.044198> PMID: 16606653
50. Lange U, Teichmann J, Müller-Ladner U, Strunk J. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study. *Rheumatology (Oxford)*. 2005; 44: 1546–1548. <https://doi.org/10.1093/rheumatology/kei082> PMID: 16263785
51. Marotte H, Pallot-Prades B, Grange L, Gaudin P, Alexandre C, Miossec P. A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. *Arthritis Res Ther*. 2007; 9: R61. <https://doi.org/10.1186/ar2219> PMID: 17597527
52. Wijbrandts CA, Klaasen R, Dijkgraaf MGW, Gerlag DM, van Eck-Smit BLF, Tak PP. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss. *Ann Rheum Dis*. 2009; 68: 373–376. <https://doi.org/10.1136/ard.2008.091611> PMID: 18408246
53. Güler-Yüksel M, Bijsterbosch J, Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Hulsmans HMJ, de Beus WM, et al. Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis. *Ann Rheum Dis*. 2008; 67: 823–828. <https://doi.org/10.1136/ard.2007.073817> PMID: 17644545
54. Gossec L, Baraliakos X, Kerschbaumer A, Wit M de, McInnes I, Dougados M, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. *Annals of the Rheumatic Diseases*. 2020; 79: 700–712. <https://doi.org/10.1136/annrheumdis-2020-217159> PMID: 32434812